FDA Signals New Testosterone Pathway - Summary - MDSpire
FDA & Government News

FDA Signals New Testosterone Pathway

Agency invites sponsors to pursue low libido indication

Share

The FDA is urging sponsors of testosterone replacement therapy (TRT) products to consider seeking approval for treating low libido in men with idiopathic hypogonadism. Currently, TRT is only approved for men with hypogonadism due to known causes. Findings from well-controlled clinical trials suggest TRT might be safe and effective for men with low testosterone and no identifiable cause of their condition. The FDA emphasizes the need for substantial evidence before any new indication can be approved, highlighting sexual health as vital to overall well-being.

Original Source(s)

FDA Signals New Testosterone Pathway

  • by Kathryn Wighton

  • April 16, 2026

Related Content

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Spectroscopy Roundup: Rover Dogs and Raman Vision

Semi-autonomous robots showcase the future of planetary exploration, as spectroscopy also reshapes lab-on-chip biology and microplastics research

  • April 14, 2026

  • 5 min
FDA Flags Missing Trial Results

Federal outreach seeks to improve compliance with ClinicalTrials.gov reporting requirements and make more complete clinical trial information publicly available